Clinical experience of using umifenovir for ARVI prevention during its seasonal increase in patients with secondary immunodeficiency conditions
Abstract. According to the data of World Health Organization, approximately 1 billion cases of seasonal acute respiratory viral infections (ARVI) are registered annually worldwide. About 3 million to 5 million of them are severe cases, resulting in 290,000 to 650,000 deaths from grippe-related respiratory complications. Patients with comorbidities, including secondary immunodeficiency conditions, are particularly vulnerable in that case.Lebedeva N.N., Maximov M.L., Malinnikova E.Yu.
The aim: to determine the prophylactic efficacy of antiviral drug umifenovir when administered at a therapeutic dose during the seasonal increase in ARVI incidence in a group of patients diagnosed with secondary immunodeficiency conditions.
Material and methods. A non-interventional study was performed in a group of patients with secondary immunodeficiency conditions during the 2024/2025 peak epidemic season.
Results. Umifenovir intake was recommended for 269 patients. A total of 197 (73%) participants followed the doctor’s recommendations, of whom 45 (22.8%) developed mild acute respiratory viral infection. In the group who did not take the drug, the number of cases was 72 (59.7%).
Conclusion. Non-interventional study demonstrated the efficacy of umifenovir, which resulted in a significant reduction in the incidence of grippe and acute respiratory viral infection in individuals with secondary immunodeficiencies, also it reduced risk of complications.
Keywords
umifenovir
secondary immunodeficiency
epidemic season
ARVI prevention
References
1. Никифорова Г.Н., Свистушкин В.М., Золотова А.В., Морозова М.А. Острые респираторные вирусные инфекции: возможности симптоматической терапии пациентов. Медицинский совет. 2021;(4):103–111. (Nikiforova GN, Svistushkin VM, Zolotova AV, Morozova MA. Acute respiratory viral infections: Possibilities of symptomatic therapy for patients. Meditsinskiy sovet = Medical Council. 2021;(4):103–111 (In Russ.)).
EDN: KRXWOQ. https://doi.org/10.21518/2079-701X-2021-4-103-111
2. Ларина В.Н., Захарова М.И., Беневская В.Ф., Головко М.Г., Соловьев С.С. Острые респираторные вирусные инфекции и грипп: этиология, диагностика и алгоритм лечения. РМЖ. Медицинское обозрение.2019;3(9–1):18–23. (Larina VN, Zakharova MI, Benevskaya VF, Golovko MG, Soloviev SS. Acute respiratory viral infections and influenza: Etiology, diagnosis and treatment algorithm. Russkiy meditsisnkiy zhurnal. Meditsinskoe obozrenie = Russian Medical Journal. Medical Review. 2019;3(9-1):18–23 (In Russ.)). EDN: TSDWRO.
3. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121(4):258–64.
PMID: 18374680. PMCID: PMC7172971. https://doi.org/10.1016/j.amjmed.2007.10.040
4. Всемирная организация здравоохранения. Грипп (сезонный). Доступ: https://www.who.int/ru/news-room/fact-sheets/detail/influenza-(seasonal) (дата обращения – 18.07.2025). (World Health Organization. Influenza (seasonal). URL: https://www.who.int/ru/news-room/fact-sheets/detail/influenza-(seasonal) (date of access – 18.07.2025) (In Russ.)).
5. ФБУЗ «Центр гигиенического образования населения» Роспотребнадзора. Грипп. Доступ: http://cgon.rospotrebnadzor.ru/content/63/3665 (дата обращения – 18.07.2025). (Center for Public Health Education of Rospotrebnadzor. Influenza. URL: http://cgon.rospotrebnadzor.ru/content/63/3665 (date of access – 18.07.2025)).
6. Семененко Т.А., Акимкин В.Г., Бурцева Е.И., Ноздрачева А.В., Симонова Е.Г., Тутельян А.В. с соавт. Особенности эпидемической ситуации по острым респираторным вирусным инфекциям с учетом пандемического распространения COVID-19. Эпидемиология и вакцинопрофилактика. 2022;21(4): 4–15. (Semenenko TA, Akimkin VG, Burtseva EI, Nozdracheva AV, Simonova EG, Tutelyan AV et al. Characteristics of the epidemic situation associated with acute respiratory viral infections in the Russian Federation during the pandemic spread of COVID-19. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention. 2022;21(4): 4–15 (In Russ.)).
EDN: ZOVUQR. https://doi.org/10.31631/2073-3046-2022-21-4-4-15
7. ФГБУ «Научно-исследовательский институт гриппа имени А.А. Смородинцева» Минздрава России. Доступ: https://www.influenza.spb.ru (дата обращения – 18.07.2025). (A.A. Smorodintsev Research Institute of Influenza. URL: https://www.influenza.spb.ru (date of access – 18.07.2025) (In Russ.)).
8. Всемирная организация здравоохранения. МКБ-11. 4A20.Y другие уточненные приобретенные иммунодефициты. Доступ: https://icd.who.int/browse/2025-01/mms/ru#609223181%2Fother%20%26%20963352150 (дата обращения – 18.07.2025). (World Health Organization. ICD-11. 4A20.Y Other specified acquired immunodeficiencies. URL: https://icd.who.int/browse/2025-01/mms/ru#609223181%2Fother%20%26%20963352150 (date of access – 18.07.2025) (In Russ.)).
9. Зайцев А.А., Акимкин В.Г., Тутельян А.В., Марьин Г.Г. Актуальные вопросы эпидемиологии, фармакотерапии и профилактики острых респираторных вирусных инфекций. РМЖ. Медицинское обозрение. 2018;2(11):53–57. (Zaitsev AA, Akimkin VG, Tutelyan AV, Maryin GG. Topical issues of epidemiology, pharmacotherapy, and prevention of acute respiratory viral infections. RMJ. Medical Review. 2018;2(11):53–57 (In Russ.)). EDN: YWYOYP.
10. Kim DK, Riley LE, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(5):158–60.
PMID: 29420462. PMCID: PMC5812470. https://doi.org/10.15585/mmwr.mm6705e3
11. Малеев В.В., Кондратьева Т.В., Красникова Т.В. Эффективность фармакотерапии гриппа и других ОРВИ в период пандемии гриппа 2009–2010 гг. Инфекционные болезни. 2010;8(4):62–65. (Maleev VV, Krasnikova TV, Kondrat’eva TV. Efficacy of pharmacotherapy of influenza and other ARVI in the period of influenza pandemia in 2009–2010. Infektsionnye bolezni = Infectious Diseases. 2010;8(4):62–65 (In Russ.)). EDN: NRENEN.
12. Hong-bo L. Multicenter randomized double blind parallel clinical trial of arbidol hydrochloride tablet in the treatment of naturally acquired influenza. Chinese J Clin Pharmacol. 2006.
13. Белоусов Д.Ю. Неинтервенционные клинические исследования. Качественная клиническая практика. 2017;(1):24–33. (Belousov DYu. Non-interventional studies. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2017;(1):24–33 (In Russ.)). EDN: ZAFDKL.
14. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antivir Res. 2009;81(2):132–40.
PMID: 19028526. https://doi.org/10.1016/j.antiviral.2008.10.009
15. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарата Арбидол®. РУ: ЛП-№(005118)-(РГ-RU) от 09.04.2024. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0d1deb3f-b075-4d45-b71b-42c326fa6a54 (дата обращения – 18.07.2025). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Arbidol. Registration certificate: ЛП-№(005118)-(РГ-RU) from 04/09/2014. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0d1deb3f-b075-4d45-b71b-42c326fa6a54 (date of access – 18.07.2025) (In Russ.)).
16. Proskurnina EV, Izmailov DY, Sozarukova MM, Zhuravleva TA, Leneva IA, Poromov AA. Antioxidant potential of antiviral drug umifenovir. Molecules. 2020;25(7):1577.
PMID: 32235534. PMCID: PMC7181215. https://doi.org/10.3390/molecules25071577
17. Ленева И.A., Фалынскова И.H., Леонова Е.И., Федякина И.Т., Махмудова Н.Р., Осипова Е.А. с соавт. Эффективность умифеновира (Арбидола) на модели экспериментальной сочетанной вирусно-бактериальной пневмонии мышей. Антибиотики и химиотерапия. 2014;59(9-10):17–24. (Leneva IA, Falynskova IN, Leonova EI, Fedyakina IT, Makhmudova NR, Osipova EA et al. Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy. 2014;59(9-10):17–24 (In Russ.)). PMID: 25975111. EDN: UCEAKN.
18. Киселев О.И., Малеев В.В., Деева Э.Г., Ленева И.А., Селькова Е.П., Осипова Е.А. с соавт. Клиническая эффективность препарата Арбидол (умифеновир) в терапии гриппа у взрослых: промежуточные результаты многоцентрового двойного слепого рандомизированного плацебо-контролируемого исследования АРБИТР. Терапевтический архив. 2015;87(1):88–96. (Kiselev OI, Maleev VV, Deeva EG, Leneva IA, Selkova EP, Osipova EA et al. Clinical efficacy of Arbidol (umifenovir) in the therapy of influenza in adults: Preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR. Terapevticheskiy arkhiv = Therapeutic Archive. 2015;87(1):88–96 (In Russ.)).
EDN: UABVON. https://doi.org/10.17116/terarkh201587188-96
About the Authors
Natalya N. Lebedeva, MD, PhD (Medicine), physician фе City Clinical Hospital No. 52 of Department of Healthcare of Moscow, senior lecturer of the Department of virology, Russian Medical Academy of Continuous Postgraduate Education of the Ministry of Healthcare of Russia. Address: 123182, Moscow, 3 Pekhotnaya St.E-mail: lebedevann3@zdrav.mos.ru
ORCID: https://orcid.org/0009-0006-8404-882X
Maxim L. Maximov, MD, Dr. Sci. (Medicine), professor, dean of the Faculty of preventive medicine and healthcare organization, Russian Medical Academy of Continuous Postgraduate Education of the Ministry of Healthcare of Russia; head of the Department of clinical pharmacology and pharmacotherapy, Kazan State Medical Academy – branch of the Russian Medical Academy of Continuous Postgraduate Education of the Ministry of Healthcare of Russia. Address: 123242, Moscow, 2/1 bldg.1 Barrikadnaya St.
E-mail: maksim_maksimov@mail.ru
ORCID: https://orcid.org/0000-0002-8979-8084. eLibrary SPIN: 6261-3982
Elena Yu. Malinnikova, MD, Dr. Sci. (Medicine), associate professor, head of the Department of virology, Russian Medical Academy of Continuous Postgraduate Education of the Ministry of Healthcare of Russia. Address: 123242, Moscow, 2/1 bldg.1 Barrikadnaya St.
E-mail: malinacgb@mail.ru
ORCID: https://orcid.org/0000-0002-5501-5707. Scopus ID: 6505810654. eLibrary SPIN: 8163-6050
Similar Articles
